Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
about
Thrombospondin-2 plays a protective role in multistep carcinogenesis: a novel host anti-tumor defense mechanism.Temporal and spatial expression of tissue inhibitors of metalloproteinases 1 and 2 (TIMP-1 and -2) in the bovine corpus luteumInfluence of Immune Myeloid Cells on the Extracellular Matrix During Cancer MetastasisCorneal neovascularization and the utility of topical VEGF inhibition: ranibizumab (Lucentis) vs bevacizumab (Avastin)Developmental and pathological angiogenesis in the central nervous systemIn vitro and in vivo anti-angiogenic activities of Panduratin ATumor Detection at 3 Tesla with an Activatable Cell Penetrating Peptide Dendrimer (ACPPD-Gd), a T1 Magnetic Resonance (MR) Molecular Imaging AgentMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesisExpression of MMP-2 correlates with increased angiogenesis in CNS metastasis of lung carcinomaCdc42 and RhoA have opposing roles in regulating membrane type 1-matrix metalloproteinase localization and matrix metalloproteinase-2 activationMechanistic Insights into the Anti-angiogenic Activity of Trypanosoma cruzi Protein 21 and its Potential Impact on the Onset of Chagasic CardiomyopathyHow matrix metalloproteinases regulate cell behaviorAntiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia.Wogonin suppresses stem cell-like traits of CD133 positive osteosarcoma cell via inhibiting matrix metallopeptidase-9 expressionAnti-invasive and antiangiogenic effects of MMI-166 on malignant glioma cellsDegradation of HER2/neu by ANT2 shRNA suppresses migration and invasiveness of breast cancer cells.Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.Expression of natriuretic peptide receptor-A in esophageal squamous cell carcinomas and the relationship with tumor invasion and migrationBrain angiogenesis in developmental and pathological processes: mechanism and therapeutic intervention in brain tumors.Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells.New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab.Matrix metalloproteinase control of capillary morphogenesis.Elevation of hemopexin-like fragment of matrix metalloproteinase-2 tissue levels inhibits ischemic wound healing and angiogenesis.Diminished corneal angiogenesis in gelatinase A-deficient mice.Intratumor IL-17-positive mast cells are the major source of the IL-17 that is predictive of survival in gastric cancer patients.Matrix metalloproteinases in tumorigenesis: an evolving paradigm.A case of tumor betrayal: biphasic effects of TIMP-1 on Burkitt's lymphomaInhibition of proliferation, migration and proteolysis contribute to corticosterone-mediated inhibition of angiogenesisComplex roles of tissue inhibitors of metalloproteinases in cancer.Angiogenesis inhibitors and radiotherapy of primary tumours.miRNA-29c suppresses lung cancer cell adhesion to extracellular matrix and metastasis by targeting integrin β1 and matrix metalloproteinase2 (MMP2)A key role of microRNA-29b for the suppression of colon cancer cell migration by American ginseng.Aldose reductase inhibition prevents hypoxia-induced increase in hypoxia-inducible factor-1alpha (HIF-1alpha) and vascular endothelial growth factor (VEGF) by regulating 26 S proteasome-mediated protein degradation in human colon cancer cellsA role for cysteine-rich 61 in the angiogenic switch during the estrous cycle in cows: regulation by prostaglandin F2alpha.Angiopoietin-2 induces human glioma invasion through the activation of matrix metalloprotease-2.siRNA suppression of hTERT using activatable cell-penetrating peptides in hepatoma cells.Models of metastatic prostate cancer: a transgenic perspective.PTEN controls tumor-induced angiogenesis
P2860
Q24535504-C124D670-93DC-4800-928E-6C8B7671B606Q24796638-1700CC20-5BAF-4152-BE48-2516F60B1053Q26767150-F5839EA4-B615-4634-8B92-47F1F64BCD40Q26823757-F44EE2A4-63A2-4EE5-931E-53D25C8BDCD4Q27023250-3FBFDA1B-C28A-45C7-B6AB-7DC7162EA579Q27301905-484787BB-23BE-4F8E-97E8-9900A3D63472Q27320124-48D5D68E-E171-43EB-8B60-FF1D445639CBQ28140740-E5B29F46-DFAC-4A3C-9949-567A636B5A71Q28300689-6A823AB5-1D8A-4B2C-A461-6CC38C8AEF2FQ28576822-94C7A931-07E4-4292-B9B7-E90F01061E61Q29248645-898C3D3F-00A6-4EC0-B0D1-649145601A7CQ29620360-2C059B10-0A8A-42F9-A5E4-12B00E41C8FDQ30399006-F63E7A33-B6EB-4338-ADC5-D5F707ABA852Q32175594-90CC51C8-766F-44FA-94C3-7E4AEA54E5D0Q33619924-AE1E67B2-408C-4F89-8EB5-A5FEBBA248FDQ33637919-99E8EF0A-EE71-4291-AD4D-C5DFE529E441Q33658836-A5CE6AA7-68D4-4BA2-ABFF-43A5CA240576Q33665623-7C234B95-2C41-4246-B416-8C1E449A1195Q33685072-AFBE58DF-A4F4-459A-B29B-24BB55AD6EC0Q33760569-F1E1E5A8-EE18-4A92-84E2-D98833BC6141Q33888492-D62FB396-15E9-4E72-8622-BCF9B09C2ECAQ33938788-86BF452A-AE19-4BFB-9FC8-EC1905297DADQ33956040-19532691-99C0-4EEE-B566-D6C6B642A6DDQ34002149-84F7A6C2-0879-4ED9-9694-163EFE4B75CCQ34014268-FE61716C-2C9C-4ACA-A765-007C6BF55CFFQ34102769-8D0D7982-BABA-4493-B307-BDFEAABC6664Q34149842-7E75A5CA-DD11-4837-A921-883836B448F0Q34199345-8FBBDB22-B801-4EFF-9058-3D8C6093A60DQ34210085-3DE61C20-B6DB-4762-AAA9-5EFC483AD279Q34441751-B53DAB25-466D-4355-8549-E158BBF6D479Q34596110-1CE8BDBE-EC5D-4978-A8C9-71E60D2FF575Q34701364-409BF169-53C0-42B2-B4C2-6D04D5BDD350Q34925168-39564925-D770-4864-87BD-213063C93A19Q35018193-5D524EA1-72BB-4D52-ADBF-C93F628CD775Q35085094-67E5E668-D75F-4BAB-AFA6-546C1831765AQ35124065-20C65716-4D5E-4052-B96B-DE41E30ABAEFQ35171149-D50BB399-8564-45DD-BCFA-4322CDC2E42EQ35207239-BFFC5EF6-9E95-424C-AEF9-3BDAFD303B65Q35217386-5613A2BC-AA5F-4FA9-87A8-6AFE31CFC6F9Q35282160-8EDBE168-99D6-42D4-85BC-95715C8AF0FD
P2860
Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
2000年论文
@zh
2000年论文
@zh-cn
name
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@ast
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@en
type
label
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@ast
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@en
prefLabel
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@ast
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@en
P2093
P2860
P356
P1476
Matrix metalloproteinase-2 is ...... nic phenotype in a tumor model
@en
P2093
C Butterfield
D Wiederschain
G Tamvakopoulos
P2860
P304
P356
10.1073/PNAS.97.8.3884
P407
P577
2000-04-01T00:00:00Z